Objective Women with overactive bladder (OAB) often undergo urodynamics before invasive treatments are considered. Ultrasound measurement of bladder wall thickness (BWT) is a less invasive, less expensive and widely available test. It has the potential to diagnose the presence of detrusor overactivity (DO). We aimed to evaluate the accuracy of BWT in the diagnosis of DO.
Introduction
Overactive bladder (OAB) is a debilitating condition that affects 12% of the world population and increases with age. 1 It is defined as a symptom complex of urinary urgency with or without incontinence, usually with increased urinary frequency, or nocturia, but absence of infection or other proven pathology. 2 It is associated with a considerable economic burden from both a societal and patient perspective. 3 At present, invasive urodynamics is the gold standard test for assessment of OAB unresponsive to conservative management. 4 It is an intimate and invasive test, with urinary tract infection (UTI) rates following urodynamics reported to be between 3% and 20%. 5 A common pathology underlying OAB is detrusor overactivity (DO), observed in 54-58% of women with symptoms. 6 At present, National Institute of Health and Care Excellence (NICE) guidance recommends treatments such as Botulinum toxin A or neurostimulation only in patients diagnosed with DO on urodynamics. 7 Bladder wall thickness (BWT) measured by ultrasonography has been proposed as a less invasive alternative to urodynamics to identify DO. A systematic review of BWT noted that all existing studies were small and of variable quality. 8 The reported sensitivity varied between 40% and 84%, and specificity between 78% and 89%. The need for further evidence was identified as a priority in a NICE guideline 7 and a Health Technology Assessment report. 9 We report results of a large prospective, multicentre test accuracy study undertaken to evaluate whether BWT measured by ultrasonography accurately can diagnose DO in women with OAB symptoms. The assessment of reproducibility of the test and the cost-effectiveness analysis are reported elsewhere. 10 
Methods

Participants
Consecutive women scheduled for investigation of OAB symptoms were prospectively approached for recruitment and consent ( Figure S1 ). Women were asked to complete a bladder diary for the 3 days preceding their test appointment.
Women were eligible for inclusion if they provided written informed consent and satisfied all the following criteria: (1) urinary frequency of nine voids or more in a 24-hour period for at least 1 day in a 3-day bladder diary; (2) mild to severe urgency recorded on at least two occasions in the bladder diary and (3) post void residual (PVR) volume <100 ml.
Exclusion criteria were: (1) symptoms of pure stress urinary incontinence (SUI) or stress-predominant mixed incontinence; (2) current pregnancy or up 6 weeks postpartum; (3) SUI surgery and/or intradetrusor Botulinum toxin A in the past 6 months; (4) urine dipstick positive for leucocytes or nitrites; (5) greater than stage II (any compartment) on pelvic organ prolapse quantification (POP-Q) system; (6) previous urodynamics in the past 6 months; or (7) current or previous use of antimuscarinics continuously for >6 months.
The clinical history of the participants was collected prior to the tests and included previous treatments for bladder problems and the International Consultation on Incontinence Questionnaire-Overactive bladder (ICIQ-OAB) questionnaire.
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Procedures
Both the bladder ultrasound and urodynamics were done within 4 weeks of each other by different practitioners. The practitioner undertaking the urodynamics was unaware of the result (blinded) of the ultrasonongraphy.
Index test-bladder wall thickness on ultrasonography A standard operating procedure (SOP) for carrying out the transvaginal ultrasound was produced and clinicians were required to attend training provided by study team.
The PVR was measured by the following formula: length 9 width 9 depth in cm 9 0.5223 in ml. The bladder wall was measured with a 7-9 MHz end-firing transvaginal probe in the sagittal plane introduced 1 cm beyond the vaginal introitus in the midline. The BWT was measured at three sites perpendicular to the luminal surface of the bladder ( Figure S2 ): the thickest part of the trigone, dome in the midline and the anterior wall. BWT was calculated as the mean of these three measurements in ml.
Reference standard-urodynamics For urodynamics, we developed an SOP based on the Good Urodynamic Practice Guidelines of the International Continence Society. 12 Women attended the clinic with a full bladder for the uroflowmetry in privacy. Filling cystometry was performed with the woman in sitting position at the rate of 100 ml/minute, followed by provocation manoeuvres and then voiding cystometry.
Detrusor overactivity was detected when involuntary detrusor contractions were seen during filling cystometry. These contractions (spontaneous or provoked) could be of variable duration and amplitude, phasic or terminal, with or without urgency and/or urgency incontinence. Voiding dysfunction was defined as abnormally slow flow (<15 ml/ second) and/or incomplete micturition (PVR > 100 ml).
Quality assurance
The lead investigator assessed the competency of local investigators by reviewing at least five ultrasound scans prior to allowing them to enter patients in the study. A reproducibility assessment done for intra-and inter-observer variation is reported elsewhere. 10 The quality of urodynamics was audited with anonymised traces every 6 months, and comparing them with the interpretation guidelines 2 to ensure ongoing quality assurance. 13 
Statistical methods
Sample size A minimum target sample size of 600 participants was prespecified to obtain estimates of sensitivities and specificities with 95% confidence intervals (CI) of a 10% width or less, anticipating sensitivity and specificity values between 70% and 95%. The computation was based on a prevalence of 50% for DO, 4 providing 300 women each for the estimate of sensitivity and specificity.
Data analysis
Sensitivity, specificity and predictive values were calculated using a BWT ≥ 5 mm indicating the presence of DO as a prespecified cut-off based on evidence from previous studies. Likelihood ratios for categories of BWT were also prespecified: <3 mm; ≥3 to <5 mm and ≥5 mm. CIs were calculated using binomial exact methods. A receiver operating characteristic (ROC) curve was constructed and the area under the curve (AUC) was computed (with 95% CI) to give an overall estimate of BWT accuracy across all thresholds. Statistical significance was tested by comparing against the uninformative model (i.e. where AUC = 0.5) using a non-parametric approach.
14 BWT measurements in groups with and without DO were compared using a twosample t-test. The relationship of BWT with pre-test ICIQ-OAB score was tested using simple linear regression. Statistical significance was defined as P < 0.05.
Sensitivity analyses were performed on the primary population to test the robustness of the results to protocol deviations (excluding those where tests were not blinded or were undertaken >4 weeks apart), missing data (incorporating measurements where not all three components of the BWT were available) and more stringent inclusion criteria (excluding those with mixed stress/urge incontinence, those with post void residual urine volume >30 ml). We also investigated the impact of using different BWT measures (trigone alone; mean of dome with measures 1 cm to the left and right of the dome).
The accuracy of BWT was compared between subgroups according to (1) previous treatment with antimuscarinics, (2) a clinical history suggesting mixed incontinence, (3) presence of a UTI in the previous 12 months, (4) voiding difficulties, (5) previous incontinence surgery and (6) BMI (<25, ≥25). ROC curves were generated for each subgroup and the AUC compared using a large sample chi-square test for independent curves. 15 Exploratory analyses were undertaken to identify variables that predicted a diagnosis of DO using multivariable logistic regression. The variables considered were BWT measurement, ICIQ-OAB scores, age, duration of symptoms, ethnicity, vaginal birth, menopausal status, parity, previous POP surgery and the subgroups listed above.
Results
Participants
A total of 687 women who were eligible and consented to participate were recruited from 22 centres between March 2011 and 2013. The study over-recruited to compensate for study withdrawals and women without complete index and reference standard test results (Figure 1) .
The mean age of women was 52.7 years (13.9 SD) and the average BMI was 30.6 (12.2 SD) ( Table 1) . Of the 687 women, 387 (55%) were postmenopausal. According to clinical history, 419 (61%) had urgency-predominant mixed incontinence and 226 (33%) reported only urinary urgency and frequency. The median duration of symptoms was 3.0 years (interquartile range 1.6-7.0).
Test completion
Complete urodynamic diagnoses were obtained in 666/687 (97%) women (Figure 1 ). Of these, 399 (60%) were diagnosed with DO (95% CI 56-64%) (Table S1 ) and 245 (61%) were given a further sub-diagnosis of DO incontinence (defined as detrusor pressure rise and leak).
All three BWT measurements (trigone, dome midline, anterior wall midline) were available in 645 (94%) women. The average BWT measurement was 4.78 mm (1.34 SD) (Table S2) .
Of the 644 participants who had the two tests (Figure 1) , both were performed on the same day in 439 (68%) and only 26 (4%) were performed more than 4 weeks apart. Ninety-seven percent of reference tests (616/632, 12 observations missing) were confirmed as being blind to the index test. No serious adverse events were reported following either test, although 49/479 (10%) of those responding at 6-month follow up reported having urine infection within 2 weeks of the test. Of these, 36/48 (one observation missing) were diagnosed by a General Practitioner. 
Estimates of test accuracy
BWT showed poor sensitivity (43%; 95% CI 38-48), specificity (62%; 95% CI 55-68), and positive (63%; 95% CI 57-69) and negative (41%; 95% CI 36-47) predictive values for diagnosis of DO (Table 2) .
Likelihood ratios were non-discriminatory at all prespecified cut-offs of ≥5 mm (1.11; 95% CI 0.92-1.35), ≥3 mm <5 mm (0.96; 95% CI 0.83-1.13) and <3 mm (0.76: 95% CI 0.46-1.26) ( Table S3) .
The ROC curve ( Figure 2 ) showed no evidence of discrimination at any threshold between those with and without DO (AUC 0.53; 95% CI 0.48-0.57; P = 0.25). There was no evidence that the mean BWT measurements were any higher in the DO-positive group than in the DO-negative group [mean (SD): 4.85 (1.36) mm versus 4.70 (1.29) mm; P = 0.19] ( Figure S3 ); or that BWT had any relation to the pre-test ICIQ-OAB symptoms score (r = -0.01; P = 0.88). The AUC remained below 0.55 in all sensitivity analyses and in all prespecified subgroups ( Figures S4-S13 and Table S4 ).
In the multivariable exploration of factors possibly associated with DO diagnosis, only higher baseline ICIQ score (worse symptoms) was associated with DO [odds ratio (OR) 1.21; 95% CI 1.13-1.29; P < 0.0001], i.e. the odds of DO diagnosis were increased by 21% for every point increase in ICIQ score (Tables S5  and S6 ).
Discussion
Summary of main findings
Bladder wall ultrasonography appeared to be no better than chance at making the diagnosis of DO, with an AUC of 0.53 (95% CI 0.48-0.57). Extensive sensitivity analyses and subgroup analyses were carried out but did not alter the interpretation of these findings. Furthermore, BWT had no relationship to ICIQ score upon presentation, indicating that it has no relationship with symptom severity. Based on this evidence, we conclude that BWT is not a useful test in diagnosing DO and should not be used in clinical practice. 
Strengths and limitations
The BUS study is the biggest test accuracy study on the subject; it was designed to minimise bias and ensure that the results would be applicable to imaging services available in routine clinical practice. We attempted to recruit consecutive women fulfilling the eligibility criteria. Women were of mixed ages and ethnicities, and were recruited from multiple centres across the UK. The prevalence of DO in our study was 60%, which was similar to other studies. 6 As transvaginal bladder ultrasound is a relatively new technique, concerns may be raised about the quality of scan measurements. However, the technique has been easy to teach and learn (personal experience of the authors) with the urinary bladder being an anterior and relatively superficial midline structure, and previously has been reported to be reproducible. 16 Both ultrasonography and urodynamics were undertaken in 94% of women, and blinding of test results ensured for 97% of them. Risk of disease progression bias was minimised by conducting the tests within 4 weeks of each other in 96% of women. All analyses and cut-offs were prespecified in the protocol. The study was powered to ensure that estimates of sensitivity and specificity would be made with adequate precision to draw robust conclusions, and we recruited beyond the target. We have undertaken multiple sensitivity analyses to investigate the impact of excluding women with variations in presentation such as urgency-predominant mixed incontinence in the study, and in all cases these additional analyses have shown no discrimination.
One area of concern is misclassification using the reference standard. 17 Urodynamics is known to be <100% reproducible in previous studies of patients with OAB and healthy volunteers. 18 Errors in the reference standard typically led to underestimation of sensitivity and specificity, but misclassification rates would have to be extreme for no relationship to be observed at all. The poor accuracy for BWT elicited in our study is thus likely to be explained mainly by the fact that BWT bears no relation to DO. This is reinforced by no relation being observed between BWT and disease severity as measured by the ICIQ-OAB questionnaire, whereas there was a strong relation between DO status from urodynamics and the ICIQ-OAB.
Interpretation in light of other evidence
The initial studies suggested a greater BWT to be an accurate diagnostic marker for DO. For a mean BWT cut-off of 5 mm, the specificity was reported to be 89% (95% CI 79-96) with a sensitivity of 84% (95% CI 76-90). 16 We identified further studies [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] which had investigated the relation between BWT measured by ultrasonography and DO, with estimates of sensitivity, specificity and AUC for bladder ultrasound varying from 37-91%, 61-97% and 0.61-0.91, respectively. 8 The published studies are mostly from a single centre (often tertiary) and there are multiple reasons to have concerns about the validity and applicability of findings. Some studies added ambulatory urodynamics to the reference standard if the patients had normal video-urodynamics, as a tie-breaker test. 16 Some studies 19, [23] [24] [25] [26] made comparisons with healthy controls, some excluded patients with mixed urinary incontinence 28 and one enriched with women with equivocal urodynamics findings. 30 Altering the spectrum of patients from that encountered in practice influences the estimates of sensitivity and specificity; 17 exclusion of the mixed urinary incontinence cases and inclusion of healthy controls will lead to overestimation of test accuracy; enrichment with difficult to diagnose cases will underestimate test accuracy. Some studies used transabdominal 23, 25, 27 or translabial ultrasound with higher interobserver variability. 26 Our study focused on recruiting women with urgency or urgency-predominant mixed incontinence undergoing urodynamics to identify DO. Some of the previous studies that compare pure SUI with OAB have assessed the value of ultrasonography to differentiate between SUI and DO: the higher observed accuracy may well reflect that BWT is higher in those with DO than SUI, 21 but this is not of direct relevance to the clinical role that ultrasonography could play.
There is some emerging evidence in the literature that the response to invasive therapies might be similar in patients with frequency and urgency with or without incontinence, regardless of the observation of DO. Everything seems to be more complicated when there is mixed incontinence involved, and urodynamics might have value there. Robustly designed randomised controlled trials are required to evaluate whether patients are more likely to benefit from decisions to use invasive therapies based on urodynamic findings of DO versus just clinical evaluation alone. 10 
Conclusion
Bladder wall thickness ultrasonography cannot identify women with detrusor overactivity and hence cannot be used to reduce the need for invasive urodynamics. Chein (Consultant Obstetrician and Gynaecologist, University of Dundee) Chair of DMC; Dr Jonathan Cook (University of Oxford) Independent Statistician; Dr Karen Ward (Consultant Urogynaecologist, Central Manchester Hospitals) Independent Clinician.
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